Teligent, Inc. Announces FDA Approval Of Erythromycin Topical Gel USP, 2%

BUENA, N.J., July 21, 2017 -- (Healthcare Sales & Marketing Network) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application ... Biopharmaceuticals, Generics, FDA Teligent, Erythromycin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news